fbpx

Azilect, 2019: Global Drug Overview, Product Profiles, Parkinson’s Disease – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Azilect”
report has been added to ResearchAndMarkets.com’s
offering.

Report Coverage

  • Drug Overview
  • Product Profiles
  • Azilect: Parkinson’s disease

Azilect (Teva/Lundbeck/Takeda) contains the pure R-isomer of rasagiline
and acts as a selective irreversible monoamine oxidase inhibitor (MAOI),
with up to 10 times more potency than selegiline and without
metabolizing into amphetamine derivatives. Azilect prolongs the activity
of dopamine in the brain to restore a measure of normal locomotion,
gait, and coordination.

Azilect was approved in Europe in February 2005 and in the US in May
2006 for the treatment of Parkinson’s disease, as a monotherapy in
early-stage patients and as an adjunctive treatment to levodopa in
moderate to advanced disease. In June 2014, the drug was approved in the
US as an adjunct to dopamine.

Azilect is marketed by Teva and Lundbeck, with the partnership providing
Lundbeck a license spanning Europe and certain Asian countries. Lundbeck
transferred sales rights in Europe back to Teva during 2016 upon the
availability of the first generics. In Japan, Teva has a separate
agreement with Takeda for the drug’s commercialization, and it was filed
for regulatory approval in June 2017.

LIST OF FIGURES

Figure 1: Azilect for Parkinson’s disease – SWOT analysis

Figure 2: The authors drug assessment summary of Azilect for Parkinson’s
disease

Figure 3: The authors drug assessment summary of Azilect for Parkinson’s
disease

Figure 4: Azilect sales for Parkinson’s disease across the US, Japan,
and five major EU markets, by country, 2016-25

LIST OF TABLES

Table 1: Azilect drug profile

Table 2: Azilect pivotal trial data in Parkinson’s disease

Table 3: Azilect sales for Parkinson’s disease across the US, Japan, and
five major EU markets, by country ($m), 2016-25

For more information about this report visit https://www.researchandmarkets.com/r/vj0q9j

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs

leverton

Content is the most important part of having quality links to your website. With Area-Info.net, we provide a quality location to share your story and include links to your website to help you grow. If you would like to learn more, visit this page to see how you can use Area-Info.net to rank higher and quicker in search engines. Contact me directly at [email protected] with any questions, or to schedule speaking engagements.

You May Also Like